growth stage

Exclusive: Houston entrepreneurial hub set to acquire local fintech startup

The Cannon has announced plans to acquire Houston-based crowdfunding startup LetsLaunch. Courtesy of Quy Tran/The Cannon

The Cannon, a Houston startup development organization with a network of coworking hubs, has announced its plans to acquire a Houston fintech startup.

LetsLaunch, an online investment platform that allows for smaller investments from non-accredited investors, has been connected with The Cannon in the past, and the two entities have even had a partnership arrangement. Now, The Cannon has plans to acquire LetsLaunch in order to provide Cannon member companies with the fundraising option.

"The Cannon and LetsLaunch have a shared vision for enabling and optimizing the innovation ecosystem," says Jon Lambert, CEO of The Cannon, in a news release. "LetsLaunch has passionately developed a technology platform that will deliver significant value to the entrepreneurial community by bringing together start-ups and investors of all kinds. By integrating the LetsLaunch platform into The Cannon's digital offerings, we will enhance the fundraising and strategic connection value we offer to our innovation community."

Lambert says the opportunity to provide The Cannon's members this opportunity to fundraise comes at an important time.

"Fundraising in the COVID-19/Post COVID-19 era is, and is likely to remain, a bit of an unknown," he continues in the release. "Adding another viable funding channel for the startups in our community who are ready for investment will be a valued benefit for our members and will provide us exposure to a whole new group of entrepreneurial investors."

The terms of the deal haven't been disclosed, but it is expected to close in June 2020. The transaction remains subject to customary closing conditions and approvals.

"We built LetsLaunch to provide broad segments of the population with a mechanism to invest in startups, while giving startups another source of capital," says Nick Carnrite, who co-founded LetsLaunch in 2018, in the release. "Crowdfunding will always remain at LetsLaunch's core, but it also became clear we had a role to play in connecting the innovation community, including startups, investors, advisors, mentors and service providers, based on their location, interests and preferences."

According to the release, the acquisition falls in line with both companies' missions to help develop an ecosystem of resources for startups.

"[LetsLaunch's] vision is completely complementary to The Cannon's goal to develop a tightly integrated innovation ecosystem," adds Brian Coyle, co-founder of LetsLaunch. "There is no better time to work together to help support private businesses."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted